In acute myelogenous leukemia (AML) intensive postremission treatment is needed for an optimal result. However, it is not known how long the treatment should last and how many courses are necessary. The object of this prospective study was to compare four and eight intensive chemotherapy cycles in the treatment of adult de novo AML. In a multicenter study, 248 consecutive patients, aged from 16 to 65 years, were treated with intensive induction treatment. The patients in remission after two courses were randomized to receive either two (short arm) or six (long arm) additional intensive cycles of chemotherapy. The median follow-up time of the living patients is 68 months. Of the patients, 77% achieved complete remission, and 36% of all patients survived for 5 years. Seventy-three patients were randomized to the short arm and 66 to the long arm. There was no significant difference in the relapse-free survival (median 21 months vs 17 months) or overall survival (43 months vs 39 months) between the short and long arms, respectively. Treatment-related deaths occurred in 31 patients (13%), 11 of them in first remission. More than onethird of the patients survived for 5 years. It seems probable that the first few months after diagnosis are decisive for the prognosis if the chemotherapy is intensive, and further treatment cannot markedly influence the outcome.
Introduction
With modern treatment protocols more than two-thirds of intensively treated patients with de novo acute myelogenous leukemia (AML) achieve remission. 1 Virtually all patients in complete remission, if left untreated, will relapse and die as a result of proliferation of occult residual leukemic cells. 2 A high relapse rate also remains a major problem in patients who receive further treatment. 1, 3, 4 A major concern in the treatment of AML is, therefore, how to preserve remission and prevent relapse.
Most studies on postremission therapy have established that maintenance treatment with low-dose chemotherapy without consolidation 5 or after consolidation [6] [7] [8] [9] [10] [11] is of little benefit. In at least two studies, however, maintenance treatment prolonged disease-free survival, 12, 13 but benefit on overall survival was not seen in one of these studies. 13 In the study by Mandelli et al, 10 prolonged duration of moderately intensive consolidation treatment had no effect on disease-free survival or overall survival 10 but such treatment significantly increased disease-free survival in a report by Ohno et al. 14 Several uncontrolled studies suggest that intensive postremission treatment is more effective than low-dose consolidation in prolonging remission. [15] [16] [17] Some controlled studies have confirmed this, 4, 5, 18 but no benefit of highly or moderately intensive postremission treatment was observed in some other studies. 19, 20 Several intensive cycles have been given in some protocols, 4, 14 but many recent approaches are based only on one, two or three courses of high-dose therapy as the sole postremission treatment. [15] [16] [17] [18] [19] [21] [22] [23] [24] Due to high morbidity, risk of mortality, and the high cost of each course of chemotherapy, it would be extremely important to know the duration of treatment necessary for a curative result, but currently the optimal number of intensive cycles is not known. The object of this prospective study was to compare four and eight intensive chemotherapy cycles in the treatment of adult patients with de novo AML.
Materials and methods

Patients
The study was opened on 1 April 1986 and closed on 31 July 1992. Two hundred and forty-eight consecutive patients aged from 16 to 66 years with AML admitted to the participating six centers were included. Patients with therapy-related leukemia, leukemia following a previous hematologic disorder or a diagnosed myelodysplastic phase of more than 3 months of duration were excluded from the study. Patients with severe liver or kidney disease (creatinine level over 400 mol/l or 4.5 mg/dl) unrelated to leukemia, clinically manifest cardiac insufficiency, or any other disease that could prevent the administration of the planned intensive cytotoxic treatment were also excluded.
There were 131 males and 117 females. The median age was 46 years, range from 16 to 65 years. The diagnosis of AML was made by standard cytological criteria according to the FAB classification. 25 Informative immunophenotype was available for 211 patients and chromosome analysis for 212 patients. The karyotypes were grouped as presented by the Cancer and Leukemia Group B. 26 In that study the favorable group included t(8;21)(q22;q22) and inv(16)(p13;q22), the intermediate group t(15;17)(q22;q12) and normal karyotype, and the unfavorable group all other abnormal karyotypes. The clinical characteristics of the patients are presented in Table 1 .
Treatment
The outline of the treatment is presented in Figure 1 . The patients in remission after two courses were randomized to receive either two or six additional intensive cycles of chemotherapy. According to the protocol the patients who had an HLA-identical sibling bone marrow donor were not randomized. The first four chemotherapy cycles were identical in both treatment arms. 2 by a continuous i.v. infusion on days 1-9, and thioguanine 75 mg/m 2 orally twice daily on days 1-9 (DAT). Patients over 60 years of age received cytarabine and thioguanine for 7 days. Cycle 2 was identical to cycle 1, and it was given to all patients except those who showed no essential decrease of blasts in bone marrow. If blasts in bone marrow were not reduced as estimated from an aspirate on the 7th day after the end of the first DAT, the disease was regarded as completely refractory to DAT and the patients (n = 30) received high-dose cytarabine and amsacrine (combination of cycle 3) instead of a second DAT. In cycle 3 amsacrine 115 mg/m Before starting a new course for a patient in remission, the neutrophil count had to be у1.5 × 10 9 /l and the platelet count у80 × 10 9 /l. In the case of persistent infection chemotherapy Outline of the treatment. If leukemia was regarded as completely refractory to the first DAT, patients (n = 30) received highdose cytarabine and amsacrine instead of a second DAT. DAT, daunorubicin + cytarabine + 6-thioguanine; HDAraC, high-dose cytarabine.
was delayed. The treatment of patients who did not achieve remission with two cycles of chemotherapy was regarded as a failure and further treatment was left to the judgement of the attending physician.
Evaluation of disease status and toxicity
Remission was defined as essentially normocellular bone marrow with less than 5% blasts, no circulating blasts, and no signs of extramedullary leukemia. Normal blood cell counts were not used as criteria, since efforts were made to continue chemotherapy as soon as it was clinically possible. Patients were considered to be in relapse if the proportion of blasts exceeded 5% in an essentially normocellular bone marrow or if there was histologically or cytologically proven extramedul-lary leukemia. During the follow-up, blood cell counts were done monthly and bone marrow aspirates were investigated every 4 months during the first 2 years in remission. Toxicity was scored according to the criteria of the World Health Organization. 27 
Statistical methods
After recovery from the second course of chemotherapy, the patients in complete remission were randomly allocated, at the central trial office by drawing consecutive sealed envelopes, to receive two or six more cycles, ie four cycles or eight cycles altogether. The envelopes, separate for each institution, were stratified by age below or over 50 years of age using a block size of four for each category. Estimation of probability of survival, relapse-free survival, and remission duration was made according to the method of Kaplan and Meier. Graphic presentation of the curves was discontinued when fewer than five patients remained at risk. Survival was calculated from the date of diagnostic bone marrow aspirate or biopsy to the date of death or most recent follow-up. Relapse-free survival was calculated from the date of first remission to the date of relapse, death, or most recent follow-up. Relapse-free survival included both relapse and death in remission as end points.
Only patients who achieved a remission were included in the estimation of relapse-free survival. Remission duration was calculated from the date of first remission to the date of relapse. Non-leukemic deaths were censored in the analysis of remission duration. Patients who were treated with allogeneic bone marrow transplantation were censored at the time of transplantation in the survival, relapse-free survival, and remission duration estimates. For continuous variables, the non-parametric Mann-Whitney test was used to compare the distribution between the two treatment groups. Comparison for categorical data was done by 2 test, whereas Fisher's exact test was used when any cell size was less than 5. Comparison of remission duration, relapse-free survival, and overall survival between the patient groups was assessed with logrank test and the generalized Wilcoxon test. All significance values were calculated from two-sided tests. Ninety-five percent confidence intervals (CI) were calculated with Greenwood's formula. 28 The analyses were performed on a VAX 6000 computer using a statistical software package (BMDP Statistical Software, Los Angeles, CA, USA). The date of analysis was 31 March 1997. The median follow-up time of the living patients is 68 months.
Ethical considerations
All treatments were given and studies were done after informed consent was obtained from all patients according to the regulations of each institution. The protocol was approved by the ethical committees of all participating centers. According to Finnish regulations the National Board of Health scrutinized the protocol before the onset of the study.
Results
Remission induction
Of the 248 patients, 192 (77%) achieved remission with one or two cycles, 36 (15%) were refractory, and 20 (8%) died. Of the patients, 132 (53% of all patients or 69% of the remission patients) achieved remission with the first cycle. Hypoplasia without remission after the first cycle was induced in 70 patients and 49 of them (70%) achieved remission with a second cycle of DAT. Thirty patients were considered completely refractory to the first cycle of DAT and they were treated with amsacrine and high-dose cytarabine. Eleven of them (37%) achieved remission (Figure 2 ). Of the patients who were refractory to protocol treatment, 32 received other induction regimens and 16 of them (50%) achieved remission. These patients were not included in the evaluations of the remission rate or duration. Induction mortality during the two cycles of induction treatment was higher in the older age groups than among young patients, being 3% (2/65) in the patients aged up to 35 years, 8% (11/133) in the patients aged from 35 to 60 years, and 14% (7/50) in the patients older than 60 years of age (test for linear trend P = 0.033).
Randomization
Of the 192 patients who achieved remission 139 were randomized, 73 to have four cycles (short arm) and 66 to have eight cycles (long arm) of chemotherapy ( Figure 3) . Fifty-three patients were not randomized for various reasons (Table 2) . Allogeneic bone marrow transplantation was the most common reason for not being randomized. Transplantation without randomization was made after one or two consolidation cycles in 25 patients and without consolidation in five patients. After randomization eight patients in the short arm and nine patients in the long arm were admitted for allogeneic bone marrow transplantation. In both arms, six patients were transplanted in first remission, two patients in second remission, and one patient in the long arm was transplanted in first relapse.
There was no significant difference between the short and long arm in age, sex, FAB subtype, white blood cell count, blast count, or incidence of poor prognostic karyotypes. The median time to remission was 36 days in both arms. The patients in the long arm had a significantly higher lactic acid dehydrogenase level but a larger proportion of them achieved remission with the first chemotherapy cycle than of the patients in the short arm (Table 3 ).
Figure 2
Results of remission induction with first DAT, and with the second cycle, which consisted of DAT or amsacrine and highdose cytarabine. DAT, daunorubicin + cytarabine + 6-thioguanine; HDAraC, high-dose cytarabine.
Figure 3
Number of patients treated with the different chemotherapy cycles. Of the 228 patients, who received cycle 2 128 were in remission and 100 had refractory disease. Cycle 2 consisted of DAT for the patients who had achieved remission after first DAT (n = 128) and for the patients who had responded to first DAT but had not achieved remission (n = 70). Patients who were completely refractory to the first DAT (n = 30), achieved amsacrine and high-dose cytarabine as a second cycle. 
Duration of remission and relapse-free survival
The median duration of remission (deaths in remission censored) was 26 months (95% CI 16-44 months), and 42% (95% CI 34-50%) of the patients did not relapse during 5 years ( Figure 4 ). Fifteen patients died in first remission due to toxicity of the treatment and three patients died of unrelated causes. The median relapse-free survival was 17 months (95% CI 14-28 months), and 62% (54-70%), 46% (38-54%), and 36% (28-44%) of the patients lived relapse-free for 1, 2, and 5 years, respectively. The plateau of the relapse-free survival curve is at 36% (Figure 4 ). There was no significant difference in the remission duration between the randomization arms. Figure 5 shows the relapse-free survival of the patients randomized to the short or long arm. The median relapse-free survival time was 21 months in the short arm and 17 months in the long arm. The difference was not significant (P = 0.777). In stratified analyses the relapse-free survival was not significantly different between the randomization arms when age, karyotype, lactic acid dehydrogenase level, or chemotherapy cycles needed to achieve remission were evaluated as covariates.
Figure 4
Projected relapse-free survival (solid line) and remission duration (broken line) of the 192 patients who achieved remission. Transplanted patients were censored at the time of transplantation. The latest relapse occurred at 3. years. The median relapse-free survival was 17 months, and the median duration of remission was 26 months. Of the patients 42% had not relapsed, and 36% lived relapsefree at 5 years. Tick marks indicate the patients at risk.
Figure 5
Projected relapse-free survival of the randomized patients. The median relapse-free survival was 21 months in the short arm and 17 months in the long arm. Of the patients 40% in the short arm and 35% in the long arm were alive and relapse-free at 5 years. There is no significant difference between the treatment arms (P = 0.777). Tick marks indicate the patients at risk.
Survival
The median survival time of all 248 patients was 33 months (95% CI 24-50 months), and 42% of the patients lived for 5 years. When transplanted patients were censored, the median survival time was 25 months (95% CI 19-41 months), and 68% (62-74%), 51% (44-58%) and 36% (28-43%) of the patients lived for 1, 2, and 5 years, respectively. The plateau of the survival curve is at 32% (Figure 6 ). Of the 195 nontransplanted patients, 116 patients have died of AML or of treatment complications, and the deaths of six patients were classified as unrelated to leukemia or to the treatment of leukemia (myocardial infarction one, suicide three, glioblastoma one, liver cirrhosis one). Three of the six patients were in first remission. All of these patients are included in the analysis of survival time.
Figure 6
Projected overall survival of the patients treated with chemotherapy. Transplanted patients were censored at the time of transplantation. The median survival was 25 months, 36% of the patients lived for 5 years and 32% for 7 years. Tick marks indicate the patients at risk. Figure 7 shows the overall survival of the patients randomized to the short or long arm. The median survival time was 43 months in the short arm and 39 months in the long arm. The difference was not significant (P = 0.421). When transplanted patients were not censored, the survival was similar in short and long treatment arms (P = 0.615). In stratified analyses with age, karyotype, lactic acid dehydrogenase level, or number of chemotherapy cycles needed to achieve remission as covariates no significant difference in survival was found between the treatment arms.
Toxicity
The median time from diagnosis to the recovery of neutrophil counts after the last (fourth) cycle in the short arm was 155 days (range 113-330 days), and to the recovery after the last (eighth) cycle in the long arm was 339 days (range 253-519
Figure 7
Projected overall survival of the randomized patients. The median survival was 43 months in the short arm and 39 months in the long arm. Of the patients 45% in the short arm and 41% in the long arm were alive at 5 years. There is no difference between the treatment arms (P = 0.421). Tick marks indicate the patients at risk. days). The longest delays between the chemotherapy courses were caused by persistent fungal infections.
The principal toxicity data are presented in Table 4 . Of the 53 patients in the long arm and in remission after four cycles, 48 (91%) received the fifth cycle, 40 (75%) received the seventh cycle, and 28 (52%) received all eight cycles (Figure 3) . The cause of discontinuation of chemotherapy was relapse in six, death in two, poor condition in seven, long hypoplasia in five, a severe skin reaction to cytarabine in one, and refusal in four patients.
Treatment-related deaths occurred in 31 patients (13%), 11 of them being in first complete remission. Two patients in the long arm died during the last four cycles due to toxicity of the treatment. High-dose cytarabine combined with daunorubicin or amsacrine proved to be the most toxic courses. Severe infections occurred in 50-66% of patients after these courses.
High-dose cytarabine caused severe neurotoxicity in some patients. When cytarabine was given for 5 days (cycle 4), five patients out of 119 (4%) experienced severe symptoms and the neurotoxic effects contributed to the death of two elderly patients. When cytarabine was given on 2 days only (cycles 3 and 8 and cycle 2 for refractory patients), four patients out of 213 (2%) had severe symptoms but none of them died.
Discussion
In Finland, with a population of five million inhabitants, all intensive treatment of acute leukemias has been centralized to the six centers participating in this study. Therefore, the patient material represents quite unselected material of patients with de novo AML who can be treated with intensive chemotherapy.
The proportion of patients achieving remission, 77%, is comparable with other multicenter studies in which the remission rates ranged between 55 and 80%. 4, 7, 12, 14, 19, 29, 30 The disease-free survival and overall survival are also comparable with other recent studies 1, 5, 19, 31, 32 and they are clearly longer than those of our previous multicenter trial with less intensive postremission therapy. 8 In this protocol an attempt was made to select refractory patients early and give them alternative chemotherapy. If blast cells were not reduced in the bone marrow 1 week after the Of the 198 patients 128 were in remission and 70 were refractory to first DAT. b This course was given to patients who were completely refractory to first DAT. DAT, daunorubicin + cytarabine + 6-thioguanine; Amsa, amsacrine; HDAraC, high-dose cytarabine; Dnr, daunorubicin; Acr, aclarubicin; Eto, etoposide; Vcr, vincristine; P, prednisone; SeqAraC, sequential cytarabine.
end of the first DAT, patients (n = 30) received a combination of high-dose cytarabine and amsacrine instead of a second DAT. The remission rate in these patients was 37% which might be acceptable in this category of patients. However, five of the 30 patients had acute promyelocytic leukemia and some of these patients may achieve remission slowly. 33 If the patients with acute promyelocytic leukemia are excluded, the remission rate in the DAT-resistant patients was only 28% (7/25) . Therefore it is evident that the effect of the combination of amsacrine and high-dose cytarabine was only moderate in the refractory patients and better alternatives for their treatment should be looked for.
Similarly to other trials, 4, 16, 17, 19, 23, 24, 30 intensive chemotherapy induced considerable toxicity, and the protocol could not be carried out exactly as planned in all cases. Currently, prognostic factors do not indicate sufficiently well which patients will tolerate and benefit from an intensive regimen. Therefore it is of importance to create an intensive protocol and allow dose reductions, treatment delays, and cessations when necessary due to excessive toxicity.
The optimal duration and quality of postremission therapy in AML are still matters of controversy. In this study we compared four and eight intensive courses of chemotherapy. In addition to the most conventional drugs in the short arm, we added into the long arm other drugs which have been successfully used in the treatment of AML, 32,34-37 eg etoposide, aclarubicin, as well as vincristine and prednisone. Furthermore, cytarabine was administered as a two-step timed sequential treatment combined with daunorubicin in one course. 16 We did not see any significant difference in the remission duration, relapse-free survival or overall survival between the short and long treatment arms. Furthermore, we could not find any subgroup which would have benefited from the prolonged treatment.
The present results are in line with studies providing evidence against the role of prolonged therapy with intensive induction and moderate or intensive consolidation. 1, 10, 20 On the other hand, a Japanese study reported a significantly longer disease-free survival when 12 moderately intensive cycles instead of four followed a consolidation phase. 14 The reasons for the different results are difficult to explain. Most results, including ours, suggest that the treatment given during the first few months after diagnosis of AML has the greatest impact on outcome.
There is also a possibility that the drugs and doses in the long arm in the present study were not sufficient to test the effect of prolonged treatment. This alternative seems, however, unlikely. The treatment was at least as intensive as in other protocols with prolonged treatment. Aclarubicin has been shown to be an effective drug in the remission induction of AML. 36 In addition, low doses of aclarubicin may induce differentation of malignant cells in acute myeloid leukemia and myelodysplastic syndrome. 38 Etoposide has achieved a recognized positition in several protocols in untreated as well as in refractory and relapsed AML. 32, 34, 35 Vincristine and corticosteroids have been previously utilized in several protocols due to their low myelotoxicity and a remission rate higher than 10% in AML. 37 However, Ohno et al 14 have recently shown that adding vincristine to daunorubicin, behenoyl cytarabine and mercaptopurine decreased the remission rate from 84 to 70%. So, vincristine does not seem to be indicated for the modern treatment of AML. However, this effect alone is unlikely to be strong enough to eliminate the effect of the four courses in the long arm. Timed sequential administration of cytarabine combined with daunorubicin has been successfully used in induction regimens. 16 Finally, amsacrine combined with standard or high doses of cytarabine has been utilized with high remission rates in both untreated and relapsed patients with AML. 39, 40 The few controlled trials, which have addressed the question of the value of alternating postremission treatment as compared with continuing the combination given for induction, have failed to show a longer duration of remission or survival. 11, 30 It is possible that dose intensity has been suboptimal in some protocols but it does not seem to be possible to increase it substantially higher than it was in the present study. A possible reason for the ineffectiveness of the alternative drugs given in these studies as well as in the present study is that they have been given too late or in a suboptimal way or combination.
More than one-third of the patients with de novo AML survived 5 years after the intensive induction and consolidation treatments and a proportion of them are probably cured of leukemia. Treatment-related deaths occurred in 31 patients (13%), 11 of them being in complete remission. Eight intensive cycles did not result in a better outcome than four cycles, mainly due to similar relapse rates in the treatment arms. It seems probable that the first few months after diagnosis are decisive for the prognosis, and further treatment cannot markedly influence the outcome if the treatment has been intensive. It is to be hoped that in the future an accurate evaluation and a better understanding of minimal residual disease will prove more useful in the determination of the optimal duration of treatment.
